Evidence map›Paper›PMID 37921125›Full record

ArticleCurrent pharmaceutical biotechnology2024

Jie Zhao, Mi Han, Yange Tian, Peng Zhao, Xuefang Liu, Haoran Dong, Suxiang Feng, Jiansheng Li

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Jie ZhaoAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
Mi HanAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
Yange TianAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
Peng ZhaoAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
Xuefang LiuAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
Haoran DongAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
Suxiang FengAcademy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
Jiansheng LiCollaborative Innovation Center for Chinese Medicine and Respiratory Diseases co-constructed by Henan Province & Education Ministry of P.R. China.ORCID 0000-0002-6485-2371
Ministry of Education · IRFirst Affiliated Hospital of Henan University · CN

Funding

Science and Technology Department of Henan Province 232102311215
6 · The paper itself

Abstract

backgroundChronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. N-acetylcysteine (NAC) is well known for its antioxidant properties, along with potential protective effects on COPD. However, the molecular mechanism of NAC against the apoptosis of alveolar epithelial cells (AECs) in COPD remains unclear.

objectiveThis study aimed to explore the anti-apoptosis effect of NAC in COPD mice and alveolar epithelial cells.

methodsIn the present study, the mouse model of COPD was established by cigarette smoke (CS), and mouse alveolar epithelial (MLE-12) cells were treated with cigarette smoke extract (CSE). TdT-mediated dUTP nick-end labeling (TUNEL) assay, reverse transcription polymerase chain reaction (RT-PCR), and western blot were performed to evaluate the effects of NAC on apoptosis, endoplasmic reticulum (ER) stress, and mitochondrial dysfunction. Meanwhile, Lbuthionine- sulfoximine (BSO), a glutathione (GSH) inhibitor, was used to uncover the mechanism of COPD treatment by NAC.

resultsWe found that NAC pretreatment could attenuate the protein levels of apoptosis, ER stress, and mitochondrial dysfunction-related genes caused by CS in vivo. Meanwhile, CSE could decrease MLE-12 cell viability, which was prevented by apoptosis inhibitor ZVAD-FMK but not necroptosis inhibitor necrostatin-1. Pretreatment of MLE-12 cells with NAC increased cellular GSH levels, inhibited cellular and mitochondrial reactive oxygen species (ROS) accumulation, and decreased protein level of apoptosis, ER stress, and mitochondrial dysfunction-related genes. Moreover, experiment results showed that BSO could completely reverse the beneficial effects of NAC.

conclusionOur study confirmed that NAC can attenuate CS-induced AEC apoptosis via alleviating ROS-mediated ER stress and mitochondrial dysfunction pathway, and the mechanism was found to be related to replenishing the cellular GSH content.

Indexed as

AcetylcysteineAlveolar Epithelial CellsApoptosisGlutathionePulmonary Disease, Chronic ObstructiveReactive Oxygen SpeciesAnimalsCell LineEndoplasmic Reticulum StressMaleMiceMice, Inbred C57BLSmokeAcetylcysteineGlutathioneReactive Oxygen SpeciesSmokealveolar epithelial cellapoptosisCOPDglutathione.N-acetylcysteinereactive oxygen species

Identifiers

PMID37921125
OpenAlexW4388302767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.